European Society of
Medical Oncology

Advancing precision oncology is a key focus of the ESMO programme, helping to analyse and understand the clinical perspective of scientific advances in cancer biology, diagnostics, and new treatments. Participants will also gain insights into the optimal roles of novel diagnostics and treatments for patients with solid tumours.

At Thermo Fisher Scientific we recognise the importance of effective biomarker testing and actionable insights in supporting better patient outcomes. By incorporating next-generation sequencing (NGS) testing in your hospital, you can access timely insights within days, rather than weeks.

Join this cosponsored Johnson & Johnson and Thermo Fisher Scientific satellite symposium featuring experts discussing topics in precision medicine. > Download agenda to discover more

Join this Johnson & Johnson and Thermo Fisher Scientific cosponsored lunch symposium  

Maximising the Synergy of Tumour Tissue and Liquid Biopsy Testing in Oncology Clinical Practice
​

Date/Time: Friday, 13 September 2024: 10:15 - 11:45 CEST

Location: Valencia Auditorium, Hall 5, Fira Barcelona Gran Via, Barcelona, Spain

> Add Event to Your Calendar

During our sponsored symposium you’ll discover more about:

• The synergy between tissue and liquid biopsy testing in the diagnosis and treatment of solid tumours
• The developing role of liquid biopsy in molecular testing and clinical practice
• The practical implementation of liquid biopsy NGS in clinical routine

> Download agenda to discover more

Chairs & Faculty

Dr. Federico Cappuzzo

Prof. Dr. Bence Sipos

Discover the power of NGS for your clinical lab with the Ion Torrent Genexus Dx Integrated Sequencer - a fast, flexible, and automated CE-marked IVD system

For In Vitro Diagnostic Use. CE-IVD according to IVDD. Not available in all countries including the United States.